Esketamine (re-assessment: depression, treatment-resistant, in combination with a SSRI or SNRI)

Subject:

• Active Substance: Esketamine
• Name: Spravato®
• Therapeutic area: Depression
• Pharmaceutical company: Janssen-Cilag GmbH

Time table:

• Start: 15.03.2023
• Final decision by G-BA: 21.09.2023

Final decision:

• Hint for a considerable additional benefit